8-K: P3 Health Partners Reports Q3 2025 Results Amid Transition

P3 Health Partners reported a 5% revenue decrease to $345.3 million in Q3 2025, alongside a $45.9 million Adjusted EBITDA loss, as it navigates a transitional year with strategic membership reductions.

Summary

• Total revenue for Q3 2025 was $345.3 million, marking a 5% decrease compared to the prior year, primarily due to intentional membership reduction and unfavorable mid-year settlement adjustments.
• Average at-risk membership for Q3 2025 was approximately 116,000 members, a 10% decrease year-over-year, reflecting previously disclosed network and payer rationalization.
• Medical margin for Q3 2025 stood at $4.4 million, or $13 PMPM, impacted by unfavorable mid-year settlement adjustments, though underlying medical cost trends remained stable when normalized.
• The Adjusted EBITDA loss for Q3 2025 was $45.9 million, or $132 PMPM.
• Year-to-date Normalized Adjusted EBITDA loss was $70.1 million, or $67 PMPM.
• Management identified $120 to $170 million in EBITDA expansion opportunities, aiming for sustainable profitability in 2026 and beyond.
• Revised fiscal 2025 guidance projects total revenues between $1,400 million and $1,450 million, medical margin between $67 million and $82 million, and an Adjusted EBITDA loss between $(110) million and $(95) million.

Sentiment

Score: 3

Explanation: While management expresses confidence in future profitability and operational progress, the current financial results show significant declines in revenue and membership, substantial losses, increased debt, and a negative equity position. The identified EBITDA expansion opportunity is forward-looking and not yet realized, and the company explicitly lists the "ability to continue as a going concern" and "potential need to raise additional capital" as key risks.

Positives

• Underlying medical cost trend, normalized for prior-year items, remained stable.
• Per-member funding improved 6% from the prior year when adjusted for prior-period items.
• Operating loss improved to $(44.2) million in Q3 2025 from $(107.0) million in Q3 2024.
• Net loss improved to $(69.5) million in Q3 2025 from $(102.9) million in Q3 2024.
• Identified $120 to $170 million in EBITDA expansion opportunities, strengthening the path to meaningful profitability in 2026 and beyond.
• Continued operational progress and expansion of the Care Enablement Model.

Negatives

• Total revenue decreased by 5% to $345.3 million in Q3 2025 compared to the prior year.
• Average at-risk membership decreased by 10% to approximately 116,000 members in Q3 2025.
• Medical margin was low at $4.4 million, or $13 PMPM, reflecting unfavorable mid-year settlement adjustments.
• Adjusted EBITDA loss was $45.9 million, or $132 PMPM, for Q3 2025.
• The company reported a stockholders' deficit of $(18.7) million as of September 30, 2025, a significant decrease from $75.9 million in equity at December 31, 2024.
• Long-term debt significantly increased to $214.2 million as of September 30, 2025, from $108.9 million at December 31, 2024.
• Net cash used in operating activities increased to $(65.5) million for the nine months ended September 30, 2025, from $(52.9) million in the prior year period.
• Interest expense, net, significantly increased to $(20.5) million in Q3 2025 from $(5.6) million in Q3 2024.

Risks

• Ability to continue as a going concern.
• Potential need to raise additional capital to fund existing operations or develop and commercialize new services or expand operations.
• Ability to achieve or maintain profitability.
• Ability to maintain compliance with debt covenants in the future, or obtain required waivers from lenders if future operating performance were to fall below current projections.
• Risk of non-cash charges to operating earnings for goodwill and/or other intangible asset impairment if there are material changes to management's assumptions.
• Ability to identify and develop successful new geographies, physician partners, payors, and patients.
• Changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to services.
• Ability to fund growth and expand operations.
• Changes in laws and regulations applicable to the business.
• Ability to maintain relationships with health plans and other key payors.
• Impact of fluctuations in risk adjustments.
• Ability to establish and maintain effective internal controls.
• Ability to maintain compliance with California regulations related to financial solvency and operational performance.
• Ability to maintain the listing of securities on Nasdaq.
• Increased labor costs and medical expense.
• Ability to recruit and retain qualified team members and independent physicians.

Future Outlook

P3 Health Partners anticipates continued operational progress and expansion of its Care Enablement Model, projecting a $120 to $170 million EBITDA expansion opportunity. This is expected to position the company for sustainable profitability in 2026 and beyond. The revised fiscal 2025 guidance forecasts total revenues between $1,400 million and $1,450 million, medical margin between $67 million and $82 million, and an Adjusted EBITDA loss between $(110) million and $(95) million.

Management Comments

• "Our core business continues to demonstrate positive momentum in the third quarter, driven by the expansion of our Care Enablement Model."
• "Medical cost trends, normalized for prior-year adjustments, remain stable, operating discipline is strengthening, and we're seeing continued traction in the markets where our model is most aligned."
• "With the progress underway, we're confident in our ability to execute on the $120 to $170 million in EBITDA expansion opportunities identified, positioning us for sustainable profitability in 2026 and beyond."

Industry Context

P3 Health Partners operates in the growing population health management and value-based care sector, which aims to improve patient outcomes and lower costs by coordinating care. The company's focus on expanding its Care Enablement Model aligns with broader industry trends towards proactive, integrated healthcare delivery, particularly for Medicare members. The intentional reduction in membership and payer rationalization suggest a strategic shift towards more aligned and potentially profitable partnerships within this evolving landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess P3 Health Partners' performance against global benchmarks or industry peers. Therefore, a detailed comparison is not possible based solely on the provided document.

Stakeholder Impact

• Shareholders: Negative impact due to declining revenue, significant losses, increased debt, and a shift to a stockholders' deficit. The 1-for-50 reverse stock split also indicates prior share price weakness.
• Employees: Potential impact from "severance expense in connection with reorganization of workforce" mentioned in the reconciliation notes.
• Customers (Patients): The "Care Enablement Model" aims to improve patient outcomes, but membership reduction could affect reach.
• Suppliers (Affiliated Primary Care Providers): The "intentional network and payer rationalization" could impact some affiliated providers.
• Creditors: Increased long-term debt and the "ability to maintain compliance with our debt covenants" risk indicate higher scrutiny and potential concern.

Next Steps

• Host a conference call and webcast on November 14, 2025, at 8:00 AM ET to discuss Q3 2025 earnings.
• Execute on identified $120 to $170 million EBITDA expansion opportunities.
• Work towards achieving sustainable profitability in 2026 and beyond.

Key Dates

Recommendation

The company faces significant financial challenges, including declining revenue and membership, substantial operating losses, a negative stockholders' equity, and a notable increase in long-term debt. While management projects future profitability, the current financial health and explicit risks, such as the "ability to continue as a going concern" and the "potential need to raise additional capital," suggest a high level of uncertainty and risk for investors. The operational improvements are not yet translating into positive financial performance, and the increased cash burn is concerning.

Keywords

P3 Health Partners, PIII, Q3 2025 Earnings, Financial Results, Population Health Management, Value-Based Care, Healthcare, Adjusted EBITDA, Medical Margin, At-Risk Membership, SEC Filing, 8-K, Earnings Report